Small Cell Lung Cancer

In a first-in-human trial, a peptide-drug conjugate showed tolerability and antitumor activity in patients with advanced solid tumors.

In this companion article, Dr Mark Socinski provides insights into the use of trilaciclib for the management of chemotherapy-induced myelosuppression in patients being treated for extensive -stage small cell lung cancer.

Gene G. Finley, MD, explains the use of conventional chemotherapy in the small cell lung cancer space.

In an interview with Targeted Oncology, Gene G. Finley discussed the many wins and losses experts have seen in the small cell lung cancer space. He also explained his hopes for the future of this space.

During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed the data supporting the use of atezolizumab and durvalumab as therapy for patients with small cell lung cancer.

Gene G. Finley, MD, explains a questions lingering on the benefit of immunotherapy in patients with small call lung cancer.

During a Targeted Oncology case-based roundtable event, Wade T. Iams, MD, discussed the case of a patient who progressed following a partial response to platinum-based chemotherapy for extensive-stage small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Ajay Kandra, MD, discussed with participants the challenges and treatment options for a patient with extensive-stage small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed the data supporting the use of immunotherapy for patients with extensive-stage small cell lung cancer.

Interim findings from the phase 1 DELLphi-300 shows that tarlatamab may induce responses in heavily-pretreated patients with small cell lung cancer.

The combination of talazoparib and temozolomide elicited an objective response rate of 39.3% in patients with extensive-stage small cell lung cancer who were relapsed or refractory to a frontline platinum-based chemotherapy regimen, according to data from a phase 2 UCLA/TRIO-US L-07 trial.

During a live virtual event, Benjamin P. Levy, MD, discussed the results of the IMpower 133 and CASPIAN trials of immunotherapy for patients with extensive-stage small cell lung cancer.

The phase 3 RESILIENT trial of irinotecan liposomal injection vs topotecan failed to meet its primary end point of overall survival in patients with previously treated small cell lung cancer.

At a live virtual event, Devika Das, MD, discussed the use of immunotherapy for patients with extensive stage-small cell lung cancer (ES-SCLC) and for patients with non–small cell lung cancer.

Following positive phase 1/2 results of DS-7300 use in patients with extensive-stage small cell lung cancer, a phase 2 study has dosed its first patient with the experimental agent.

During a Targeted Oncology case-based roundtable event, Mohamed K. Mohamed, MD, PhD, discussed with participants the challenges of treating extensive-stage small cell lung cancer and their views of the CASPIAN and IMpower 133 trial results.

During a Targeted Oncology case-based roundtable event Thomas E. Stinchcombe, MD, discussed the case of a 53-year-old patient with extensive-stage small cell lung cancer.

During a case-based roundtable event, Joshua K. Sabari, MD, discussed the case of a 73-year-old woman with extensive-stage small cell lung cancer.

Eric S. Nadler, MD of Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment of the IMpower133 trial in patients with extensive-stage small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Antoinette Wozniak, MD, discussed the results of the IMpower 133 and CASPIAN trials of new agents for treating extensive-stage small cell lung cancer.

Orphan drug designation has been granted by the FDA to PT217 for patients with small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed with participants the results of the CASPIAN and IMpower 133 trials of new regimens for extensive-stage small cell lung cancer.

Lurbinectedin in combination with pembrolizumab in the second-line shows promising safety and efficacy in relapsed small cell lung cancer

Adding tiragolumab to atezolizumab plus carboplatin and etoposide did not meet its mark of improving survival in patients with extensive-stage small-cell lung cancer.

Based on phase 3 study results of patients with extensive-stage small cell lung cancer, treatment with adebrelimab plus chemotherapy prolonged overall survival compared with matched placebo.